How big is Rigel Pharmaceuticals, Inc.?

As of Jun 18, Rigel Pharmaceuticals, Inc. has a market capitalization of 342.44 million and reported net sales of 203.08 million with a net profit of 37.18 million over the latest four quarters.

As of Jun 18, Rigel Pharmaceuticals, Inc. has a market capitalization of 342.44 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 203.08 million, while the sum of net profit for the same period is 37.18 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 3.29 million, and total assets amount to 493.21 million.

What does Rigel Pharmaceuticals, Inc. do?

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for immune and hematological disorders, cancer, and rare diseases. As of March 2025, it reported net sales of $53 million and a market cap of $342.44 million.

Overview: <BR>Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in discovering, developing, and providing novel small molecule drugs for immune and hematological disorders, cancer, and rare diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 53 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 342.44 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.91 <BR>Return on Equity: 200.24% <BR>Price to Book: 18.44<BR><BR>Contact Details: <BR>Address: 1180 Veterans Blvd, SOUTH SAN FRANCISCO CA: 94080-1985 <BR>Tel: 1 650 6241100 <BR>Website: https://www.rigel.com/

Should I buy, sell or hold Rigel Pharmaceuticals, Inc.?

Who are in the management team of Rigel Pharmaceuticals, Inc.?

As of March 2022, the management team of Rigel Pharmaceuticals, Inc. is led by Mr. Raul Rodriguez as President and CEO, supported by independent directors including Mr. Bradford Goodwin, Mr. Keith Katkin, Dr. Brian Kotzin, Mr. Gregg Lapointe, and Mr. Gary Lyons.

As of March 2022, the management team of Rigel Pharmaceuticals, Inc. includes Mr. Raul Rodriguez, who serves as the President, Chief Executive Officer, and Director. The Board of Directors also comprises several independent directors: Mr. Bradford Goodwin, Mr. Keith Katkin, Dr. Brian Kotzin, Mr. Gregg Lapointe, and Mr. Gary Lyons. <BR><BR>In summary, as of March 2022, the key management figure is Mr. Raul Rodriguez, with a supporting Board of Directors made up of independent directors.

Is Rigel Pharmaceuticals, Inc. overvalued or undervalued?

As of September 12, 2025, Rigel Pharmaceuticals is considered very attractive due to its undervalued P/E ratio of 10, a low PEG ratio of 0.01, and strong performance with a 157.59% return over the past year, significantly outperforming the S&P 500.

As of 12 September 2025, Rigel Pharmaceuticals, Inc. has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, as indicated by its P/E ratio of 10, significantly lower than the industry average, and a PEG ratio of 0.01, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 7.92, further supporting the undervaluation thesis.<BR><BR>In comparison to its peers, Rigel Pharmaceuticals has a P/E of 7.49, while 2seventy Bio, Inc. shows a much higher P/E of 76.93, indicating that Rigel is trading at a substantial discount. Scilex Holding Co. also presents a negative P/E, highlighting the relative strength of Rigel's valuation metrics. Over the past year, Rigel has returned 157.59%, outperforming the S&P 500's 17.14%, which reinforces the attractiveness of its current valuation.

Is Rigel Pharmaceuticals, Inc. technically bullish or bearish?

As of July 21, 2025, Rigel Pharmaceuticals has shifted to a bullish trend, supported by positive MACD and moving averages, despite a mildly bearish signal from Dow Theory, and has outperformed the S&P 500 with a 157.59% return over the past year.

As of 21 July 2025, the technical trend for Rigel Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting a positive outlook. Daily moving averages are also bullish, while Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish signal on the weekly chart, which slightly tempers the overall bullish sentiment.<BR><BR>In terms of performance, Rigel Pharmaceuticals has significantly outperformed the S&P 500 over the past year, with a return of 157.59% compared to the S&P 500's 17.14%. Despite recent short-term declines, the longer-term trend remains strongly bullish.